Long Term Results and Complications After Epistaxis Treatment

Nosebleed (Epistaxis) - Posterior or Anterior Clinical Trial

Official title:

Langzeitresultate Und Komplikationen Nach Einer Epistaxisbehandlung

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02127554
• Other study ID #: SM_21_01_2014
• Secondary ID: KEK-ZH-Nr: 2013-
• Status: Completed
• Phase: N/A
• First received: April 28, 2014
• Last updated: December 1, 2015
• Start date: January 2014
• Est. completion date: December 2015

Study information

• Verified date: December 2015
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Observational

Clinical Trial Summary

The aim of this study is to find the most agreeable and in the long term most efficient treatment for epistaxis.

Description:

In the general population epistaxis occurs quite frequently. Approximately 60% of persons will be affected once in their lifetime, and 6% thereof will seek medical advice. Thereby anterior and posterior epistaxis are discerned. Anterior epistaxis is usually located at the Locus Kisselbachii, while posterior bleeds are found further back in the nose. There, most bleeds will originate from the A. sphenopalatina or the A. ethmoidalis.

Different treatment modalities exist. Anterior epistaxis are usually easier to treat than posterior ones. The aim of this study is to find the most efficient treatment. This involves the assessment of long term results and potential sequelae. Existing data will be complemented with information about recurrences and complications. The question is: Which treatment method leads to the least numbers of recurrences in the long term with the fewest long term sequelae?

Secondly, the most agreeable, least painful treatment method is to be identified. Therefore we will send out questionnaires to patients that were treated between March 29, 2007 and April 1st, 2008 at the Zurich University Hospital.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 591
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 14 Years to 80 Years

Eligibility

Inclusion Criteria:

All patients treated during the study period with known address and who did not decease in the meantime.

Exclusion Criteria:

Insufficiently filled out questionnaires; Obvious lack of ability to remember (as tested by control questions); Known mental disability

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Epistaxis
• Nosebleed (Epistaxis) - Posterior or Anterior

Locations

Country	Name	City	State
Switzerland	Zurich University Hospital	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of complications due to treatment		Up to 8 years post-treatment	Yes
Other	Sequelae due to treatment		Up to 8 years post-treatment	No
Primary	Number of patients without recurrence		Up to 8 years post-treatment	Yes
Secondary	Discomfort caused by treatment		Up to 1 day post-treatment	No